Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell–Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19). (26th October 2020)

• Record Type: Journal Article
• Authors: Malsy, Jakob; Veletzky, Luzia; Heide, Janna; Hennigs, Annette; Gil-Ibanez, Ines; Stein, Alexander; Lütgehetmann, Marc; Rosien, Ulrich; Jasper, Dorothea; Peine, Sven; Hiller, Jens; Haag, Friedrich; Schmiedel, Stefan; Huber, Samuel; Jordan, Sabine; Addo, Marylyn M; Schulze zur Wiesch, Julian
• Is Part Of: Clinical infectious diseases. Volume 73:Number 11(2021)
• Page Start: e4020
• Page End: e4024
• Publication Date: 2020-10-26
• Subjects: COVID-19 -- obinutuzumab -- follicular lymphoma -- convalescent plasma -- remdesivir; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciaa1637
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: We provide detailed clinical, virological, and immunological data of a B-cell–depleted patient treated with obinutuzumab for follicular lymphoma with protracted coronavirus disease 2019 (COVID-19) and viremia. A sustained response was achieved after 2 courses of remdesivir and subsequent convalescent plasma therapy. Immunocompromised patients might require combined and prolonged antiviral treatment regimens.